Alnylam Pharmaceuticals (ALNY) Return on Capital Employed Growth (3y) (2013 - 2026)
Alnylam Pharmaceuticals (ALNY) Return on Capital Employed Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -356.00 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -516.00 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -2,309.00 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4,967.00 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,424.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 513.00 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5,777.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 109.00 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5,210.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5,777.00 |
| Mar 31, 2026 | 4,853.00 |
| Dec 31, 2025 | 4,288.00 |
| Sep 30, 2025 | 3,813.00 |
| Jun 30, 2025 | 2,040.00 |
| Mar 31, 2025 | 1,916.00 |
| Dec 31, 2024 | 1,893.00 |
| Sep 30, 2024 | 1,808.00 |
| Jun 30, 2024 | 3,017.00 |
| Mar 31, 2024 | 2,227.00 |
| Dec 31, 2023 | 2,004.00 |
| Sep 30, 2023 | 1,932.00 |
| Jun 30, 2023 | 613.00 |
| Mar 31, 2023 | 1,988.00 |
| Dec 31, 2022 | 1,609.00 |
| Sep 30, 2022 | 812.00 |
| Jun 30, 2022 | 1,796.00 |
| Mar 31, 2022 | 2,921.00 |
| Dec 31, 2021 | 3,159.00 |
| Sep 30, 2021 | 2,144.00 |